Zevra Therapeutics reports third-quarter revenue of $37.76M
Net income was $19.21M and diluted EPS was $0.26. A year earlier, revenue was $26.06M and the company reported a $544K net loss, with diluted EPS of a loss of $0.01 per share.
Zevra Therapeutics reported third-quarter 2026 revenue of $37.76M and net income of $19.21M, compared with $26.06M in revenue and a $544K net loss in the prior-year quarter. Diluted EPS was $0.26, versus a loss of $0.01 per share.Financial Highlights¹ Reported as “Revenue, net”. ² Reported as “Net…